FTC makes final its consent order to approve GlaxoSmithKline merger

01-Feb-2001

GlaxoSmithKline plc (LSE/NYSE:GSK) today announces that, following a period of public comment, the US Federal Trade Commission (FTC) has made final its consent order to approve the merger of Glaxo Wellcome and SmithKline Beecham. The FTC vote to finalise the consent decree was 5-0.

When the FTC approved the terms of the consent decree on 18th December 2000 it stated that it would continue investigating the potential effects of the merger in the area of smoking cessation products. The FTC has voted 5-0 to close its investigation into this area.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance